Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | BRD4 | O60885 | 2/20 | 0.48 |
| ▸ | NPC1 | O15118 | 1/20 | 0.48 |
| ▸ | ESR1 | P03372 | 2/20 | 0.43 |
| ▸ | CCR2 | P41597 | 2/20 | 0.42 |
| ▸ | POLB | P06746 | 2/20 | 0.42 |
| ▸ | HTT | P42858 | 1/20 | 0.42 |
| ▸ | PLA2G2A | P14555 | 1/20 | 0.41 |
| ▸ | GPR35 | Q9HC97 | 1/20 | 0.40 |
| ▸ | SRC | P12931 | 1/20 | 0.40 |
| ▸ | MEN1 | O00255 | 2/20 | 0.39 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.39 |
| ▸ | CFTR | P13569 | 2/20 | 0.39 |
| ▸ | PPARG | P37231 | 2/20 | 0.39 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL4802191 | 0.83 | CCR2 (0.59) | BRD4ESR1CCR2POLBHTT | |
| SCHEMBL31402270 | 0.83 | CCR2 (0.59) | BRD4ESR1CCR2POLBHTT | |
| SCHEMBL27616419 | 0.79 | PLA2G2A (0.47) | NPC1CCR2PLA2G2A | |
| SCHEMBL5100347 | 0.79 | ALDH1A1 (0.46) | NPC1CCR2PLA2G2AGPR35PPARG | |
| SCHEMBL6211323 | 0.79 | CCR2 (0.49) | BRD4CCR2KMT2APPARG | |
| SCHEMBL6823869 | 0.79 | NPC1 (0.50) | BRD4NPC1ESR1CCR2HTT | |
| SCHEMBL27663338 | 0.78 | CCR2 (0.71) | CCR2GPR35 | |
| SCHEMBL6823478 | 0.78 | ESR1 (0.52) | NPC1ESR1CFTR | |
| SCHEMBL4417815 | 0.77 | NPC1 (0.41) | BRD4NPC1ESR1POLBHTT | |
| SCHEMBL1808695 | 0.76 | PGR (0.44) | BRD4CCR2POLBHTT |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 15 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-1756096-B1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | HOFFMANN LA ROCHE (CH) | 2009-08-12 | — | — | EP | disclosed |
| US-7485652-B2 | Indolyl derivatives as liver-X-receptor (LXR) modulators | HOFFMANN-LA ROCHE INC. (US) | 2009-02-03 | — | — | US | disclosed |
| US-7459478-B2 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2008-12-02 | — | — | US | disclosed |
| US-20070099916-A1 | Indolyl derivatives as liver-x-receptor (LXR) modulators | DEHMLOW HENRIETTA | 2007-05-03 | — | — | US | disclosed |
| CN-1950365-A | Indolyl derivatives as liver-X-receptor modulators | HOFFMANN LA ROCHE (CH) | 2007-04-18 | — | — | CN | disclosed |
| EP-1756096-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F.HOFFMANN-LA ROCHE AG (CH) | 2007-02-28 | — | — | EP | disclosed |
| US-7173048-B2 | Indolyl derivatives as liver-X-receptor (LXR) modulators | HOFFMANN-LA ROCHE INC. (US) | 2007-02-06 | — | — | US | disclosed |
| US-20060270728-A1 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-11-30 | — | — | US | disclosed |
| US-7101903-B2 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitiors of plasminogen activator inhibitor-1 (PAI-1) | WYETH (US) | 2006-09-05 | — | — | US | disclosed |
| CN-1726029-A | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (pai-1) | WYETH CORP (US) | 2006-01-25 | — | — | CN | disclosed |
| WO-2005105791-A1 | INDOLYL DERIVATIVES AS LIVER-X-RECEPTOR MODULATORS | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-10 | — | — | WO | disclosed |
| US-20050245515-A1 | Indolyl derivatives as liver-X-receptor (LXR) modulators | F. HOFFMANN-LA ROCHE AG (CH) | 2005-11-03 | — | — | US | disclosed |
| EP-1569639-A2 | SUBSTITUTED DIHYDROPYRANO INDOLE-3,4-DIONE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | Wyeth (US) | 2005-09-07 | — | — | EP | disclosed |
| US-20050113436-A1 | 9-(4-Methylbenzyl)-6-[4-(trifluoromethoxy)phenyl]-1,9-dihydropyrano[3,4-b]indole-3,4-dione; treating fibrinolytic disorders, vein thrombosis and coronary heart disease, and pulmonary fibrosis | WYETH (US) | 2005-05-26 | — | — | US | disclosed |
| WO-2004052893-A2 | SUBSTITUTED DIHYDROPYRANO INDOLE-3,4-DIONE DERIVATIVES AND 3-OXOACETIC ACID SUBSTITUTED 2-HYDROXYMETHYLINDOLE DERIVATIVES AS INHIBITORS OF PLASMINOGEN ACTIVATOR INHIBITOR-1 (PAI-1) | WYETH (US) | 2004-06-24 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20050113436-A1 | 9-(4-Methylbenzyl)-6-[4-(trifluoromethoxy)phenyl]-1,9-dihydropyrano[3,4-b]indole-3,4-dione; treating fibrinolytic disorders, vein thrombosis and coronary heart disease, and pulmonary fibrosis | FGB, SERPINE1, MMP1 | BRD4 259/4885NPC1 2392/4885ESR1 3195/4885 |
| US-20050245515-A1 | Indolyl derivatives as liver-X-receptor (LXR) modulators | INSR, NR1H2, NR1H3 | BRD4 1204/4885NPC1 129/4885ESR1 161/4885 |
| US-20070099916-A1 | Indolyl derivatives as liver-x-receptor (LXR) modulators | INSR, NR1H2, NR1H3 | BRD4 1204/4885NPC1 129/4885ESR1 161/4885 |
| US-20060270728-A1 | Substituted dihydropyrano indole-3,4-dione derivatives as inhibitors of plasminogen activator inhibitor-1 (PAI-1) | SERPINE1, TFPI, F2 | BRD4 355/4885NPC1 1904/4885ESR1 2906/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.